CD33-Targeted Antibody & Cell Therapy
CD33-Targeted Antibody & Cell Therapy – Target Pipeline List 05/2019
Targets: CD33; Myeloid Cell Surface Antigen CD33; Sialic Acid-Binding Immunoglobulin-Like Lectin 3
This Target Pipeline List provides an overview of CD33-targeted antibody cell therapeutics in development for treatment of acute myeloid leukemia.
CD33 is a cell surface antigen that is present in more than 80% of patients with acute myeloid leukemia (AML), but is absent from pluripotent hematopoietic stem cells. AML is a rapidly progressing, life-threatening blood and bone marrow cancer. If left untreated, patients with AML will die within months, if not weeks, of their disease. AML is the most common type of acute leukemia in adults and accounts for approximately 80% of all cases of acute leukemia. About 1/33,000-1/25,000 people are expected to be newly diagnosed with AML in Europe annually.
The approval in the US and Europe of the first CD33-targeted antibody-drug conjugate has spurred the development of further efficacy-enhanced antibody-based and cell-based treatment modalities currently in preclinical and clinical development. Among them are enhanced naked antibody, novel antibody-drug conjugates (ADC), bispecific T-cell engaging (BiTE) antibodies, other bispecific antibodies and radioimmunotherapeutics (RIT). Chimeric antigen receptor (CAR) T-cells are an adoptive cell therapy approach for treatment of AML
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.